ValuEngine upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning.

Several other analysts have also commented on the stock. Wedbush set a $79.00 price target on shares of Ascendis Pharma A/S and gave the company a buy rating in a research report on Thursday, August 30th. Wells Fargo & Co lifted their price target on shares of Ascendis Pharma A/S from $83.00 to $88.00 and gave the company an outperform rating in a research report on Thursday, August 30th. BidaskClub lowered shares of Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, October 9th. Credit Suisse Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Friday, November 9th. They set an outperform rating and a $80.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Ascendis Pharma A/S from a buy rating to a hold rating in a research report on Tuesday, November 13th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $77.56.

Shares of Ascendis Pharma A/S stock opened at $64.67 on Wednesday. The company has a market cap of $2.72 billion, a PE ratio of -14.94 and a beta of 0.82. Ascendis Pharma A/S has a 1-year low of $36.07 and a 1-year high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.23) by $0.29. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. Research analysts predict that Ascendis Pharma A/S will post -4.01 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. purchased a new stake in Ascendis Pharma A/S in the second quarter valued at approximately $350,000. Quantitative Systematic Strategies LLC purchased a new stake in Ascendis Pharma A/S in the second quarter valued at approximately $361,000. Meadow Creek Investment Management LLC raised its position in Ascendis Pharma A/S by 12.1% in the second quarter. Meadow Creek Investment Management LLC now owns 6,952 shares of the biotechnology company’s stock valued at $462,000 after purchasing an additional 748 shares during the period. Glen Harbor Capital Management LLC raised its position in Ascendis Pharma A/S by 12.1% in the second quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 952 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Ascendis Pharma A/S by 153.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 5,107 shares during the period. 95.60% of the stock is currently owned by institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Read More: Bond

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.